• In recent months, Novavax has moved away from directly selling COVID-19 vaccines and is instead prioritizing licensing its Matrix-M adjuvant technology to larger pharmaceutical partners, while investors have also been watching potential opportunities linked to the Cyclospora outbreak and the upcoming second-quarter earnings report.
• This pivot toward a licensing-centric model marks a significant shift in how Novavax aims to generate revenue and share development risk with bigger drugmakers.
• Next, we’ll examine how Novavax’s new focus on licensing its Matrix-M adjuvant could reshape the company’s existing investment narrative.

Find 52 companies with promising cash flow potential yet trading below their fair value.

Novavax Investment Narrative Recap

To own Novavax today, you really need to believe its future lies in turning Matrix M into a broad, partner powered licensing business rather than a pure COVID vaccine play. The recent focus on licensing, and investor interest in Cyclospora related potential, does not materially change the near term catalyst: the Q2 2026 earnings report. The biggest risk right now is that milestone and royalty income from partners proves slower or smaller than hoped, straining cash flow and liquidity.

Among recent developments, the January 2026 Pfizer license and option agreement looks most relevant to this shift. Pfizer paid Novavax an upfront US$30.0 million for a non exclusive global Matrix M license in at least one field, with the option for a second. This type of deal sits at the heart of the new licensing focused narrative and could be a template for how future catalysts, and partner execution risk, show up in Novavax’s results.

Yet for all the promise around Matrix M and new partnerships, investors should be aware that Novavax’s dependence on a few key partners means...

Novavax's narrative projects $348.5 million revenue and $55.9 million earnings by 2028.

Uncover how Novavax's forecasts yield a $13.78 fair value, a 80% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were already baking in around US$306.6 million of 2028 revenue and US$38.4 million of earnings, so you should expect their partnership heavy story and concerns about concentrated partner risk to evolve as new licensing deals and outbreaks either reinforce or challenge those assumptions.

Explore 4 other fair value estimates on Novavax - why the stock might be worth just $13.78!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Novavax research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Novavax research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Novavax's overall financial health at a glance.

Want Some Alternatives?

Our top stock finds are flying under the radar-for now. Get in early:

• The future of work is here. Discover the 35 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.